Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The FDA approved Atebrioz (zilurgisertib) tablets for adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. The companies said the treatment will be available in the U.S. in October through Mirum Access Plus, and the agency issued Incyte a rare pediatric disease priority revie
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older…